AttardLab
@AttardLab
Followers
1K
Following
55
Media
35
Statuses
246
Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
Joined January 2018
Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich Please follow
ecancer.org
Dr Elena Castro (Hospital Universitario 12 de Octubre, Madrid, Spain), Dr Pasquale Rescigno (Newcastle University, Newcastle, UK), Prof Gert Attard (University
0
3
4
🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 https://t.co/U46NMslfll 📅 Key Dates: 🔹 Submission opens: 1 Sept
0
15
18
The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via https://t.co/fPN1UjMfsX!
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology https://t.co/uUnQ6N6A13 CAPItello-281 In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor
1
9
37
@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA
0
13
28
CAPItello-281 In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now With Amplitude trial paving the way, NGS is key in
#ESMO25 Ph III CAPItello 281: Capivasertib + Abiraterone vs pbo + Abi in PTEN-deficient de novo mHSPC rPFS 33.2 vs 25.7 mo (HR 0.81); OS not yet mature ⚠️ A promising first in class targeted option for this poor-prognosis population Benefit ↑ w/greater PTEN loss, emphasizing
0
10
29
Publication of CAPItello-281 Ph 3 trial in @Annals_Oncology at end of @fizazi_karim #ESMO25 👍 https://t.co/yL1UyK2quR
0
1
2
Wonderful discussion by @Prof_Nick_James on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 @myESMO @OncoAlert
2
11
24
EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25
0
3
12
1
2
4
STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.
3
6
23
ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.
4
26
65
🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel. 🧬 cell cycle gene amplification associates with taxane resistance 🤝Results from an international collaborative effort
0
0
0
Our latest manuscript with #demichelislab - detailed analysis of ctDNA sequentially collected from metastatic prostate cancer pts receiving cabazitaxel.
1
0
10
Precision medicine enters hormone sensitive prostate cancer therapeutics ! The first of many to follow
💫🌟Niraparib + Abiraterone + Prednisone in HRR-deficient mCSPC.🌟💫 https://t.co/35fsV1AVsS
@AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine
0
8
29
AMPLITUDE trial of niraparib abi just published - 1st confirmation of efficacy with PARPi in HRR-mutant mHSPC, with notable benefit in the BRCA subgroup.
nature.com
Nature Medicine - In the randomized phase 3 AMPLITUDE trial, patients with HRR-deficient mCSPC experienced longer progression-free survival when they were treated with niraparib and AAP compared to...
1
20
41
ICYMI 👇 our latest study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer https://t.co/Ax9Bcetnp9 Please share!
Excited to share our study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer @EmilyGrist1 @marina_parry @MRCCTU @uclcancer @ProstateUK @PCFnews @Prof_Nick_James @LotanLab @Decipher_VCYT @ChrisSweens1
1
6
12
Please share with all interested colleagues!
🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 https://t.co/LdNISUG3OK 📅 Key Dates: 🔹 Submission opens: 1 Sept
0
18
40